XKRX
003520
Market cap141mUSD
Oct 08, Last price
1,035.00KRW
1D
-3.18%
1Q
-12.51%
Jan 2017
-88.27%
Name
Yungjin Pharm Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Yungjin Pharm. Co., Ltd. engages in the development, production, and distribution of pharmaceuticals. Its products include cephalosporin, antibiotics, drugs for the central nervous system, cardiovascular, endocrine system, urinary system, respiratory, anti-inflammatory and analgesics, anti-histamine, anti-fungal, total nutrition, vitamin and supplement, cosmetics, and tonic drinks. The company was founded on July 16, 1962 and is headquartered in Seoul, South Korea.
Key people
Wung Gyu Lee
Vice President · since 2024
Gyeong Bo Kang
Managing Director · since 2023
Wung Yeol Yang
Managing Director · since 2024
Jung Yeon Cho
Assistant Managing Director · since 2023
Byeong Ho Park
Assistant Managing Director · since 2024
Assistant Managing Director · since 2023
Gi Su Lee
President, Chief Executive Officer, Director · since 2022
Yeong Yeop Goh
Non-Executive Independent Director · since 2023
Won Seop Kim
Non-Executive Independent Director · since 2023
Bung Nyeon Kim
Non-Executive Independent Director · since 2022
Non-Executive Independent Director · since 2025
Valuation
Title KRW in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||